Deal adds drug analysis to Millipore offerings

Millipore is establishing a beachhead extending its reach into Europe, the home turf of competitor Sartorius Stedim Biotech, through the acquisition of U.K.-based BioAnaLab, a specialist service provider for biologic drug and vaccine analysis.

The deal lets Millipore further establish its biopharmaceutical services business and fortify its status as an outsource partner, according to a company announcement. BioAnaLab brings GMP support testing capabilities and its customer base to the deal. The Oxford company was spun out of the University of Oxford in 2002.

For its part, Goettingen, Germany-based Sartorius Stedim announced in July that it is partnering with cell culture media specialist SAFC Biosciences to provide fluid management and liquid/powder system solutions for upstream and downstream processing. The deal is expected to further the German company's offerings of single-use bioprocess technology.

- see the Millipore announcement
- here's the Sartorius Stedim release

Suggested Articles

Transporting pharmaceutical products at <-60C for more than 96 hours has seemed an insurmountable challenge. TOWER’s solution has solved the problem.

Roche will spend $500 million for a new global manufacturing logistics hub in Canada that will eventually employ 500 workers in Ontario.

Fledgling Indiana CDMO Incog BioPharma Services is shelling out $60 million to get its first manufacturing facility off the ground.